ANGPTL3 and atherosclerosis: The ANGPTL3 gene is another potential target for gene-editing therapies, as naturally occurring loss-of-function mutations in ANGPTL3 have no long-term health consequences and are associated with hypolipidemia and lower risk of ASCVD [90].